Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Beta-blockers after ACS
Commentary:
Associate Professor Rohan Rajaratnam Liverpool and Campbelltown Hospitals,
Sydney
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Acute STEMI
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
‘Indefinite’ beta-blockers in secondary prevention
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
2012 observational study
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
2012 observational study: Prior MI
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
2012 observational study: Prior MI
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Almost all evidence for the benefits of beta-blockers after an acute coronary syndrome was obtained at least 20 years ago. Management of ACS, particularly the use of effective reperfusion, has changed very markedly since then.
• Despite the lack of evidence from the modern era of ACS management, current clinical guidelines continue to recommend the long-term use of beta-blockers, from 3 years to indefinitely.
• Adherence with long-term medication after ACS is often suboptimal. In patients with preserved left ventricular function who are seeking to reduce their treatment burden, there is no evidence that beta-blockers are effective and cessation of the beta-blocker may be appropriate.
Commentary: Associate Professor Rohan Rajaratnam
Related Documents
